CFI-401870

CFI-401870 is an orally active threonine tyrosine kinase (TTK (Mps1) ) inhibitor with an IC50 of 3.1 nM. CFI-401870 exhibits IC50s against PLK4, KDR, AURKA and other kinases such as AURKB/INCENP were all greater than 1 μM.CFI-401870 inhibits the growth of various cancer cells, causing chromosome lag, an increase in aneuploidy and cell cycle arrest. CFI-401870 can be used for the study of cancers such as colon cancer[1].

Product Specifications

CAS Number

[1430741-35-7]

UNSPSC

12352005

Target

DNA/RNA Synthesis; Mps1

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O[C@@H]1C[C@H](CC[C@@H]2C1)N2C3=CC=C(C=C3)C4=NNC5=C4C=C(C=C5)C(N[C@H](C6CC6)C7=NC=CC=C7)=O

Molecular Formula

C30H31N5O2

Molecular Weight

493.60

References & Citations

[1]Liu Y, et al. The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3- (4- (heterocyclyl) phenyl) -1H-indazole-5-carboxamides as Anticancer Agents. J Med Chem. 2015 Apr 23;58 (8) :3366-92.